Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Jan 6;17(1):156.
doi: 10.3390/cancers17010156.

Learning from Other Tumors: Pathways for Progress and Overcoming Challenges in Cholangiocarcinoma

Giulia Tesini  1   2 , Chiara Braconi  2   3   4 , Lorenza Rimassa  1   5 , Rocio I R Macias  6
Affiliations
Editorial

Learning from Other Tumors: Pathways for Progress and Overcoming Challenges in Cholangiocarcinoma

Giulia Tesini et al. Cancers (Basel). .

Abstract

Cholangiocarcinoma (CCA) is a group of complex and heterogeneous tumors originating from the epithelial cells of bile ducts that can occur in intrahepatic, perihilar, or distal localizations [...].

PubMed Disclaimer

Conflict of interest statement

G.T. has no competing conflicts of interest to declare. L.R. reports grant/research funding (to institution) from AbbVie, Agios, AstraZeneca, BeiGene, Eisai, Exelixis, Fibrogen, Incyte, IPSEN, Jazz Pharmaceuticals, Lilly, MSD, Nerviano Medical Sciences, Roche, Servier, Taiho Oncology, TransThera Sciences, and Zymeworks, consulting fees from AbbVie, AstraZeneca, Basilea, Bayer, Bristol Myers Squibb, Eisai, Elevar Therapeutics, Exelixis, Genenta, Hengrui, Incyte, IPSEN, IQVIA, Jazz Pharmaceuticals, MSD, Nerviano Medical Sciences, Roche, Servier, Taiho Oncology, and Zymeworks, lecture fees from AstraZeneca, Bayer, Bristol Myers Squibb, Guerbet, Incyte, IPSEN, Roche, and Servier, and travel expenses from AstraZeneca. She is chair for the EORTC GITCG HBP/NET Task Force, treasurer for the International Liver Cancer Association, and Special Expert Clinical Trials Europe for NCI GISC Hepatobiliary (HB) Task Force (unpaid positions). C.B. received honoraria as speaker (Astrazeneca, Incyte, Servier) and consultant (Incyte, Servier, Boehringer Ingelheim, Astrazeneca, Tahio, Jazz Pharmaceuticals, Molecular Partners), received research funds (Avacta, Medannex, Servier), and her spouse is an employee of AstraZeneca. R.I.R.M. reports institutional funds from AstraZeneca, Incyte, Servier, Taiho, and Jazz Pharmaceuticals.

References

    1. Banales J.M., Marin J.J.G., Lamarca A., Rodrigues P.M., Khan S.A., Roberts L.R., Cardinale V., Carpino G., Andersen J.B., Braconi C., et al. Cholangiocarcinoma 2020: The next horizon in mechanisms and management. Nat. Rev. Gastroenterol. Hepatol. 2020;17:557–588. doi: 10.1038/s41575-020-0310-z. - DOI - PMC - PubMed
    1. Vithayathil M., Khan S.A. Current epidemiology of cholangiocarcinoma in Western countries. J. Hepatol. 2022;77:1690–1698. doi: 10.1016/j.jhep.2022.07.022. - DOI - PubMed
    1. Izquierdo-Sanchez L., Lamarca A., La Casta A., Buettner S., Utpatel K., Klümpen H.-J., Adeva J., Vogel A., Lleo A., Fabris L., et al. Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. J. Hepatol. 2022;76:1109–1121. doi: 10.1016/j.jhep.2021.12.010. - DOI - PubMed
    1. Marin J.J., Lozano E., Briz O., Al-Abdulla R., Serrano M.A., Macias R.I. Molecular Bases of Chemoresistance in Cholangiocarcinoma. Curr. Drug Targets. 2017;18:889–900. doi: 10.2174/1389450116666150223121508. - DOI - PubMed
    1. National Lung Screening Trial Research Team. Aberle D.R., Adams A.M., Berg C.D., Black W.C., Clapp J.D., Fagerstrom R.M., Gareen I.F., Gatsonis C., Marcus P.M., et al. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. N. Engl. J. Med. 2011;365:395–409. doi: 10.1056/nejmoa1102873. - DOI - PMC - PubMed

Publication types

LinkOut - more resources